

How to Cite:

Abbas, H. H., & Flayyih, M. T. (2022). Enhancement of meropenem potency by methotrexate nanoparticles. *International Journal of Health Sciences*, 6(S6), 8012–8018.
<https://doi.org/10.53730/ijhs.v6nS6.12197>

Enhancement of meropenem potency by methotrexate nanoparticles

Hassan Hufdhly Abbas

Department of Biology, college of Science, University of Baghdad, Baghdad, Iraq
*Corresponding author email: hassanhufdy75@gmail.com

May Talib Flayyih

Department of Biology, college of Science, University of Baghdad, Baghdad, Iraq

Abstract--The MTX was converted to MTX nanoparticles by the modified method based on changing the pH gradually. For the first time MTX NPs+Meropenem complex were prepared and evaluated as a potential tool to overcome antimicrobial resistance and to improve pharmacokinetics of the drug, the results showed that the antibacterial activity of complex (MTX NPs plus MEM) has increased (from 1(µg/ml) to <0.5(µg/ml) for p1, from 2(µg/ml) to 1(µg/ml) for p10 and from 8(µg/ml) to 4(µg/ml) for p48).

Keywords--MTX, MTX NPs, UV-Vis spectra analysis, AFM, SEM, FTIR, MEM.

Introduction

Meropenem, under the brand name Merrem, is an intravenous β -lactam antibiotic used to treat a variety of bacterial infections. It is in the carbapenem family of medications[1]. Meropenem usually results in bacterial death through blocking their ability to make a cell wall[2]. The spectrum of action includes many Gram-positive and Gram negative bacteria (including Pseudomonas) and anaerobic bacteria. The overall spectrum is similar to that of imipenem, although meropenem is more active against Enterobacteriaceae and less active against Gram-positive bacteria[3]. Meropenem exerts its bactericidal action by binding to penicillin-binding proteins (PBPs) in the bacterial cell wall and inhibiting peptidoglycan cross-linking associated with cell wall synthesis, which ultimately leads to cell death[4,5].

Multidrug resistant (MDR) bacteria have become an extremely serious public health concern. Bacteria can develop resistance through various mechanisms[6,7]. However, various types of NPs are still considered to be non-toxic and are used to reduce the toxicity hazards of other therapeutic agents[8].

Antibiotic resistance has become one of the biggest threats to public health worldwide due to the misuse and abuse of antibiotics. Combined use of nanoparticles (NPs) with conventional antibiotics constitutes a promising alternative for fighting antibiotic resistance as NPs could restore the activity of the existing antibiotics [9,10]. Interactions of antibiotics with nanoparticles is the most common among studies dedicated to the testing of combined action of nanoparticles with antibiotics and moreover some studies have found that the efficacy of antimicrobial agents can be enhanced by combining them with nanoparticles against different pathogens, including *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Escherichia coli* [11,12].

Methods

Methotrexate (MTX) nanoparticles preparation and characterization

Synthesis of methotrexate nanoparticles from methotrexate done in nanotechnology lab, Department of Biotechnology, College of Science, University of Baghdad by [13]. The characterization of prepared nanoparticles were measured by Atomic force microscopy (AFM), Fourier-transform infrared spectroscopy (FTIR), Ultraviolet (UV) spectrophotometer and Scanning electron microscopy (SEM).

MTX nanoparticles plus Meropenem (MTX Nps-MEM) complex

In the current study, MTX Nps- MEM complex was prepared, which is a component of MTX nanoparticles plus Meropenem in a 1: 1 ratio, according to the following method:

- The mixture of 5 ml of MTX nanoparticles (MIC) concentration was prepared previously and 5 ml of Meropenem (16,8,4,2,1 and 0.5 µg/ml).
- The mixture was put in the ultrasonic path at 4500 kh for 25 min.
- The characterization of prepared complex nanoparticles was measured by Fourier-transform infrared spectroscopy (FTIR).

Determination of Minimal Inhibitory Concentration of MTX Nps- MEM complex against *Pseudomonas aeruginosa* by micr titer plate method

Micro-titer plate's method [14] with some modifications was used as the follows:

- *Pseudomonas aeruginosa* isolates were inoculated on nutrient broth and incubate for 24 hrs at 37°C.
- Mueller Hinton broth was prepared.
- Micro-titer plates of 96 flat well were used in this method.
- One hundred µL of prepared Mueller Hinton broth was placed in all wells of the plate (in the first horizontal line) except the last well (well number 12).
- Meropenem dilutions were prepared between: 0.5 -16µg/ml
- Meropenem plus Methotrexate nanoparticles concentrations were prepared by adding (MIC) of MTX NPs for dilutions of meropenem (16,8,4,2,1,0.5 µg/ml).

- One hundred μL of every dilution of Meropenem and Meropenem plus methotrexate nanoparticles complex was putted in the wells that market for each one and mixed very well
- Inoculums were prepared, by transferring 3-5 colonies into a tube of 5ml of normal saline to obtain culture with $1.5 \times 10^8 \text{CFU/ml}$, and adjusting to turbidity standard of McFarland 0.5, suspensions were used within 30 min. of preparation.
- Ten μL of bacterial suspension was added to the wells .
- The positive and negative controls were prepared in Last line of plate .
- Sixteen μL of resazurin pigment was added to all the wells.
- Plate was incubated at 30°C for 18 – 24 hours.
- The lowest concentration of antimicrobial agent that completely inhibits the growth was considered the minimal inhibitory concentration (MIC).

Result

MTX nanoparticles preparation and characterization

The MTX was converted to Methotrexate nanoparticles by the modified method based on changing the pH gradually .The characteristics of MTX nanoparticles were done by using UV-Vis Spectroscopy, atomic force microscope (AFM), scanning electron microscope (SEM) and fourier-transform infrared spectroscopy (FTIR) analysis.UV-Vis spectra analysis showed absorption peak at 405nm for MTX NPs. The results of AFM showed the existence of a number of nanoparticles with different diameters, but the average of these diameters was 57.11 nanometres. SEM showed the prepared MTX nanoparticles were typically nanoparticles (57.11nm diameter) with spiny or needle shape ,FTIR showed the possible functional groups of biomolecules involved in MTX NPs .The above analysis proved strongly that the particles that prepared from MTX were typically nanoparticles[13].

Preparation and characterization of MTX NPS-MEM complex

MTX NPs-MEM complex were prepared by using the minimum inhibitory concentration (MIC) of MTX NPs ($62.5 \mu\text{g/ml}$) that added to serial concentration of Meropenem (MEM) (16,8,4,2,1 and $0.5 \mu\text{g/ml}$) in 1:1 ratio of volume and Formation of complex confirmed by FTIR. The FTIR spectrum of meropenem (MEM) showed that absorption peaks located at about $3438.84\text{-}3409.91$, $3001.03\text{-}2935.46$, 1575.73 , and 1423.37 cm^{-1} in the region $400\text{-}4000 \text{ cm}^{-1}$. The peaks at $3438.84\text{-}3409.91 \text{ cm}^{-1}$ assigned to O-H stretching and N-H stretching, The band at $3001.03\text{-}2935.46 \text{ cm}^{-1}$ associated with C-H stretching , The band at 1575.73 cm^{-1} corresponds to the N-O stretching ,The peak at 1423.37 assigned to O-H bending as shown in figure (1).




Figure 1. FTIR analysis of (meropenem)

The FT-IR spectrum of MTX-NPs + meropenem complex showed that absorption peaks located at about 3427.27, 2360.71-2329.85, 1639.38, 1556.45, 1413.72, and 642.25-524.60 cm^{-1} in the region 400-4000 cm^{-1} . The peaks at 3427.27 cm^{-1} assigned to O-H stretching and N-H stretching, The band at 2360.71-2329.85 cm^{-1} associated with the O=C=O, The band at 1639.38 cm^{-1} corresponds to the C=C stretching, The peak at 1556.45 assigned to N-O stretching, The peaks at 1413.72 cm^{-1} assigned to O-H bending, and the peaks at 642.25-524.60 cm^{-1} assigned to metal oxygen, as shown in figure (2).




Figure 1.2. FTIR analysis of MTX NPs + meropenem complex

Table 1
Frequency of Absorption, Bonds and Functional group of MEM and MEM-MTX NPs complex

Materials	Frequency Absorption (cm^{-1})	of Bonds	Compound class of Functional Groups
MTX NPs + Mem complex	808.12	C-H bending	Alkene
	642.25-524.60	Metal Oxygen	-
	3427.27	O-H stretching N-H stretching	Alcohol, phenols, Amine

Meropenem	2360.71-2331.78	O=C=O stretching	Carbon dioxide
	1639.38	C=C stretching	Alkene
	1556.45	N-O stretching	Nitro compound
	1413.72	O-H bending	Alcohol
	642.25-524.60	Metal Oxygen	-
	3438.84-3409.91	O-H stretching N-H stretching	Alcohol, phenols, Amine
	3001.03-2935.46	C-H stretching	Alkane
	1575.73	N-O stretching	Nitro compound
	1423.37	O-H bending	Alcohol

Antibacterial effect of MTX NPs-MEM complex by micro titer plate

The minimum inhibition concentrations (MICs) of MTX NPs-MEM complex were evaluated against four *P. aeruginosa* isolates (three isolate p1, p10 and p48 were MDR and one isolate p29 was sensitive to antibiotics) by Microtiter plate, as shown in figure (3).




Figure 3. Antibacterial effect of MTX NPs-MEM complex by micro titer plate

The results of MICs for MTX Nps-MEM complex showed in table(2).

Table 2
The minimum inhibition concentration of MTX and MTX NPs

Isolate	MEM MIC ($\mu\text{g/ml}$)	Complex (MEM+MTX NPs) Conc ($\mu\text{g/ml}$)	Complex MIC ($\mu\text{g/ml}$)
p1	1	125+(16,8,4,2,1,0.5)	125+<0.5
p10	2	31.25+(16,8,4,2,1,0.5)	31.25+1
p29	<0.5	62.5+(16,8,4,2,1,0.5)	62.5+<0.5
p48	8	62.5+(16,8,4,2,1,0.5)	62.5+4

For the first time MTX NPs+Meropenem complex were prepared and evaluated as a potential tool to overcome antimicrobial resistance and to improve pharmacokinetics of the drug, the results showed that the antibacterial activity of complex (MTX NPs plus MEM) has increased (from 1($\mu\text{g/ml}$) to <0.5 ($\mu\text{g/ml}$) for p1 , from 2($\mu\text{g/ml}$) to 1($\mu\text{g/ml}$) for p10 and from 8($\mu\text{g/ml}$) to 4($\mu\text{g/ml}$) for p48) as shown in the table(3.5).[11] observed that meropenem and ZnO NPs showed indifference effect on *P. aeruginosa* . The result by [15] that showed a high efficiency Meropenem silver nanoparticles (mer-AgNPs) that increased antibacterial activity against both Gram-positive and Gram-negative bacteria and [16] showed a high loading efficiency of Meropenem into mesoporous silica nanoparticles (MSN-NH₂-MEP) against multidrug-resistance (MRD) *A. baumannii*. In other hand [17] the enhanced activity of antibiotics combined with silver NPs, especially meropenem, was weaker against non-resistant bacteria than against resistant bacteria and [18] showed a higher antibacterial activities of the drug-loaded nanoparticles (meropenem-loaded chitosan nanoparticles) were observed against methicillin-sensitive and methicillin-resistant *Staphylococcus aureus*, *Escherichia coli* and *Klebsiella pneumoniae*, as compared to the free drug.[19] was found that VAuNPs in combination with meropenem better potentiation effects against *P. aeruginosa* than that of vanillin alone . This study observed the effect of MTX NPs on the potency of meropenem against *P.aeruginosa* and indicate the enhancement of meropenem potency when used as complex(meropenem+MTX NPs).

References

1. Abbas HH & Flayyih MT.(2022) . Synthesis and characterization of methotrexate nanoparticles .International Journal of Health Sciences,
2. Abdelkader A, El-Mokhtar MA, Abdelkader O, Hamad MA, Elsabahy M, El-Gazayerly ON. Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model. Carbohydrate polymers. 2017 Oct 15;174:1041-50.
3. Al Baloushi AE. Characterization of Carbapenemase Producer Enterobacteriaceae Isolated in the United Arab Emirates.
4. Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M, Rafailovich M. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert review of anti-infective therapy. 2011 Nov 1;9(11):1035-52.
5. Andrews JM. Determination of minimum inhibitory concentrations. Journal of antimicrobial Chemotherapy. 2001 Jul 1;48(suppl_1):5-16.
6. Arya SS, Sharma MM, Das RK, Rookes J, Cahill D, Lenka SK. Vanillin mediated green synthesis and application of gold nanoparticles for reversal of antimicrobial resistance in *Pseudomonas aeruginosa* clinical isolates. Heliyon. 2019 Jul 1;5(7):e02021.
7. Cho JC, Zmarlicka MT, Shaer KM, Pardo J. Meropenem/vaborbactam, the first carbapenem/ β -lactamase inhibitor combination. Annals of Pharmacotherapy. 2018 Aug;52(8):769-79.
8. Eleftheriadou I, Giannousi K, Protonotariou E, Skoura L, Arsenakis M, Dendrinou-Samara C, Sivropoulou A. Cocktail of CuO, ZnO, or CuZn nanoparticles and antibiotics for combating multidrug-resistant

- Pseudomonas aeruginosa* via efflux pump inhibition. *ACS Applied Nano Materials*. 2021 Aug 20;4(9):9799-810
9. Elsaesser A, Howard CV. Toxicology of nanoparticles. *Advanced drug delivery reviews*. 2012 Feb 1;64(2):129-37.
 10. Jayaprakash J, Sankari D, Johnthomas P, Johnmilton D, Swaminathan C, Sathish M, Ganesh M. Antibacterial and anti bio film activities of novel antibiotic conjugated silver nanoparticles. *Materials Today: Proceedings*. 2022 Jan 1;49:2836-41.
 11. Mamun MM, Sorinolu AJ, Munir M, Vejerano EP. Nanoantibiotics: functions and properties at the nanoscale to combat antibiotic resistance. *Frontiers in chemistry*. 2021 May 13;9:687660.
 12. Najafi M, Moghaddam MN, Yousefi E. The effect of silver nanoparticles on pyocyanin production of *Pseudomonas aeruginosa* isolated from clinical specimens. *Avicenna Journal of Medical Biotechnology*. 2021 Apr;13(2):98.
 13. oxide nanoparticles and various antibiotics combination against *Pseudomonas aeruginosa* clinically isolated bacterial strains. *Saudi Journal of Biological Sciences*. 2021 Jan 1;28(1):928-35.
 14. Pålsson-McDermott EM, O'Neill LA. Targeting immunometabolism as an anti-inflammatory strategy. *Cell research*. 2020 Apr;30(4):300-14.
 15. Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. *International Journal of Health Sciences*, 6(1), i-v. <https://doi.org/10.53730/ijhs.v6n1.5949>
 16. Terreni M, Taccani M, Pregolato M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. *Molecules*. 2021 May 2;26(9):2671.
 17. Vivas R, Barbosa AA, Dolabela SS, Jain S. Multidrug-resistant bacteria and alternative methods to control them: an overview. *Microbial Drug Resistance*. 2019 Jul 1;25(6):890-908.
 18. Wang S, Gao Y, Jin Q, Ji J. Emerging antibacterial nanomedicine for enhanced antibiotic therapy. *Biomaterials Science*. 2020;8(24):6825-39.
 19. Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. *Computer Applications in Engineering Education*, 29(3), 550–561. <https://doi.org/10.1002/cae.22202>
 20. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PR, Walkty A, Denisuik A, Golden A, Gin AS. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem- β -lactamase inhibitor combinations. *Drugs*. 2018 Jan;78(1):65-98.
 21. Zhu Y, Hao W, Wang X, Ouyang J, Deng X, Yu H, Wang Y. Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug-resistant infections. *Medicinal Research Reviews*. 2022 Jan 4.